Summary
Extended-release (ER) opioid formulations are often targeted for misuse and abuse because they contain high amounts of opioid. An oral abuse-deterrent formulation of ER morphine sulfate tablets (morphine ARER [abuse-resistant extended-release], MorphaBondTM ER) resists physical manipulation and chemical extraction, forms a nonsyringeable material in liquid environments, and retains its ER characteristics despite manipulation. Morphine ARER is formulated with multiple overlapping physiochemical barriers instead of antagonists or aversive agents to deter misuse and abuse. When crushed and taken intranasally, morphine ARER has a 40% lower mean maximum drug-liking score than crushed intranasal morphine ER.
Register to download
Pharmacokinetic Charcateristic of Oral_Intranasal Morphine ARER
You may also be interested in:
White Paper
Strategies for Accelerating Rare Disease Clinical Development
Rare disease trials differ from those in most other therapeutic areas because the indications are more complex and involve smaller patient…
Poster
Human Abuse Liability Studies: Not Your Traditional Phase I Study
Abuse potential refers to the likelihood for a drug to be used in nonmedical situations for its positive psychoactive effects. PRA Health Sciences’…
Blog